Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tulathromycin - unknown - tulathromycin antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

quimica sintetica, s.a. - tulathromycin - unknown - tulathromycin antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - tulathromycin - unknown - tulathromycin antibiotic active 0.0 - active constituent

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - tulathromycin - antibacterials for systemic use - pigs; cattle; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis sensitive to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis sensitive to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica sensitive to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. draxxin should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

elanco gmbh - tulathromycin - antibacterials for systemic use - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - tulathromycin - antibacterials for systemic use - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

ceva santé animale - tulathromycin - antibacterials for systemic use - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - tulathromycin - parenteral liquid/solution/suspension - tulathromycin antibiotic active 100.0 mg/ml - antibiotic & related

European Union - English - EMA (European Medicines Agency)

vetoquinol - tulathromycin - antibacterials for systemic use - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

European Union - English - EMA (European Medicines Agency)

vmd n.v. - tulathromycin - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.